Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2025-01-08 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Reply to Clarification- Financial results
Interim / Quarterly Report Classification · 95% confidence The document is a detailed response to a regulatory query from the National Stock Exchange of India regarding the company's financial results for the quarter and half year ended September 30, 2024. It includes extensive financial data such as unaudited standalone and consolidated cash flow statements, with year-to-date figures and comparative data for the previous period. The document references compliance with Indian Accounting Standards (IndAS 34) for interim financial reporting and provides detailed financial statements rather than just an announcement or summary. The presence of condensed financial statements for a period shorter than a full fiscal year (half year ended September 30, 2024) and the detailed financial data confirm that this is an Interim / Quarterly Report. It is not a mere announcement or certification, but contains substantive financial data and analysis for the interim period. H1 2025
2025-01-08 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges (BSE and NSE) regarding the appointment of a senior management personnel, specifically the new CEO of India Consumer Healthcare at Piramal Pharma Limited. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosures about changes in management. The content includes a brief profile of the appointed individual and does not contain financial data, earnings, or report details. The document length is 3681 characters, which is relatively short and focused solely on management appointment. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2025-01-06 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing about a change in the name of the Registrar and Share Transfer Agent of the company. It does not contain any financial data, report, or detailed information about company performance or governance changes. It is an announcement to stock exchanges for record-keeping purposes. The document length is only 1342 characters, indicating it is a brief communication. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-01-02 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about a change in the name of the company's Registrar and Transfer Agent (RTA). It does not contain financial data, management discussion, voting results, or any detailed report. The length is only 1314 characters, indicating it is a brief announcement. It is not a report itself but an update on a corporate administrative change. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-01-02 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 100% confidence The document is an update on litigation involving Piramal Pharma Limited, specifically informing stock exchanges about a settlement agreement related to a civil suit. It references a previous intimation and provides details about the settlement amount and its financial impact. The document is short (2127 characters) and serves as a notification rather than a detailed report or financial statement. It does not contain financial data, audit information, or management discussion. The content fits the category of a Legal Proceedings Report, which covers updates on significant lawsuits or regulatory actions involving the company.
2024-12-06 English
Giving guarantees/indemnity/ becoming a surety for third party
Capital/Financing Update Classification · 95% confidence The document is a notification under Regulation 30 of the SEBI Listing Regulations about the issuance of a corporate guarantee by the company on behalf of its subsidiary. It is an update on a financing-related transaction, specifically a contingent liability arising from a corporate guarantee. The document does not contain financial statements or detailed financial analysis, nor is it a report or presentation. It is an announcement related to capital or financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear mention of corporate guarantee issuance and financing arrangements.
2024-11-08 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.